203 related articles for article (PubMed ID: 32615091)
1. Clinical Impacts of EGFR Mutation Status: Analysis of 5780 Surgically Resected Lung Cancer Cases.
Suda K; Mitsudomi T; Shintani Y; Okami J; Ito H; Ohtsuka T; Toyooka S; Mori T; Watanabe SI; Asamura H; Chida M; Date H; Endo S; Nagayasu T; Nakanishi R; Miyaoka E; Okumura M; Yoshino I;
Ann Thorac Surg; 2021 Jan; 111(1):269-276. PubMed ID: 32615091
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between mutations of epidermal growth factor receptor gene and clinicopathologic features of non-small cell lung cancers].
Wang F; Fu S; Tang T; Deng L; Zhang X; Li YZ; Shao JY
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):664-6. PubMed ID: 22321543
[TBL] [Abstract][Full Text] [Related]
3. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
Sasaki H; Endo K; Takada M; Kawahara M; Kitahara N; Tanaka H; Okumura M; Matsumura A; Iuchi K; Kawaguchi T; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Lung Cancer; 2006 Oct; 54(1):103-8. PubMed ID: 16890322
[TBL] [Abstract][Full Text] [Related]
4. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
Kaneda T; Yoshioka H; Tamiya M; Tamiya A; Hata A; Okada A; Niwa T; Shiroyama T; Kanazu M; Ishida T; Katakami N
BMC Cancer; 2018 Jan; 18(1):6. PubMed ID: 29291705
[TBL] [Abstract][Full Text] [Related]
5. EGFR and erbB2 mutation status in Japanese lung cancer patients.
Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
[TBL] [Abstract][Full Text] [Related]
6. [Mutation status of epidermal growth factor receptor and KRAS gene in non-small cell lung cancers at Xuanwei regions of Yunnan Province].
Yang CS; Pan XY; Feng Q; Wang YY; Xu WM; Jiang T; Wang L; Yang JL; Wang L
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):226-30. PubMed ID: 27033384
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
8. [Epidermal growth factor receptor gene mutations and clinicopathologic correlation in 309 patients with non-small cell lung cancer].
Feng Q; Li XH; Chen Z; He JS; Wang CX; Zhou LX; Xue WC
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):660-3. PubMed ID: 22321542
[TBL] [Abstract][Full Text] [Related]
9. [Relationship of epidermal growth factor receptor gene mutations, clinicopathologic features and prognosis in patients with non-small cell lung cancer].
Fan MJ; Li HG; Lü ZQ; Zhang HZ; Shen XM
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):679-82. PubMed ID: 22321547
[TBL] [Abstract][Full Text] [Related]
10. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma.
Yotsukura M; Yasuda H; Shigenobu T; Kaseda K; Masai K; Hayashi Y; Hishida T; Ohtsuka T; Naoki K; Soejima K; Betsuyaku T; Asamura H
Lung Cancer; 2017 Jul; 109():45-51. PubMed ID: 28577949
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
Takamochi K; Oh S; Matsunaga T; Suzuki K
J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
[TBL] [Abstract][Full Text] [Related]
14. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
15. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
[TBL] [Abstract][Full Text] [Related]
16. Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer.
Kuijpers CCHJ; Hendriks LEL; Derks JL; Dingemans AC; van Lindert ASR; van den Heuvel MM; Damhuis RA; Willems SM
Lung Cancer; 2018 Jul; 121():76-81. PubMed ID: 29858031
[TBL] [Abstract][Full Text] [Related]
17. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
Kaneda T; Hata A; Tomioka H; Tanaka K; Kaji R; Fujita S; Tomii K; Katakami N
Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
[TBL] [Abstract][Full Text] [Related]
19. EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients.
Choi YW; Jeon SY; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Koh YW; Han JH; Sheen SS
Am J Clin Oncol; 2018 Apr; 41(4):385-390. PubMed ID: 26967328
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implication of EGFR mutation status and subtype in resected lung adenocarcinoma patients irrespective of therapy.
Li R; Li Q; Lin S; Li W; Yu L; Wang L; Dong X; Yu L; Li S; Liu W; Li B
Clin Transl Oncol; 2019 Mar; 21(3):298-303. PubMed ID: 30022385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]